Acutaas Chemicals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

ACUTAAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.1%Reaction day

₹1164.60

prior close

₹1190.00

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.1%+4.2% vs market

Pharmaceuticals peers, median of 149sector-0.1%+4.2% vs sector

On the reaction day the stock moved 4.2 pts more than Nifty Smallcap 250 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-2.7

15m

-3.7

30m

-2.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.1-0.1+4.2-0.1+4.2

Next day

+15.0-1.0+16.0-1.1+16.1

+12.0-2.6+14.6-3.1+15.1

+13.9-1.7+15.5-2.4+16.2

+14.3-2.0+16.3-2.7+17.0

+12.2-3.2+15.4-4.2+16.4

+9.9-4.5+14.4-4.4+14.3

15d

+20.4-1.4+21.8-4.4+24.8

+21.6-3.4+24.9-5.1+26.7

+13.2-3.6+16.9-7.0+20.2

+47.0+0.5+46.4-6.3+53.2

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 149Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Acutaas Chemicals (formerly Ami Organics) reported strong Q1 FY26 results. Consolidated revenue from operations rose ~17% YoY to ₹207.24 crore (vs ₹176.67 crore in Q1 FY25), while consolidated net profit surged nearly 3x to ₹44.01 crore (vs ₹14.69 crore). Standalone numbers were even stronger, with revenue up ~20% YoY to ₹205.97 crore and profit tripling to ₹44.65 crore. Basic EPS stood at ₹5.41 (consolidated) and ₹5.45 (standalone), reflecting the recent stock split from ₹10 to ₹5 face value. The company highlighted investments in subsidiary Acutaas Advance Material (up to ₹199.99 crore), a new South Korea JV (Indichem Inc. with J & Materials), and 100% utilization of the ₹99.10 crore preferential issue proceeds. The auditor's limited review report was clean with no modifications.

Likely market impact

Sharp YoY profit growth of ~200% and healthy margin expansion signal strong operating momentum, likely to be viewed positively by investors. However, sequential QoQ decline (revenue down ~33% vs Q4 FY25) suggests some quarter-on-quarter volatility typical of the specialty chemicals business.